Palibone (Risedronate Monosodium Hemi-Pentahydrate)

Risedronate Monosodium Hemi-Pentahydrate, the active ingredient in Palibone, is a bisphosphonate presented as a oral tablet for systemic use. It treats osteoporosis and other bone‑loss conditions in post‑menopausal women and men at risk of fracture. GNH USA supplies Palibone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palibone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Risedronate is indicated for disorders that affect bone remodeling and density.

- Osteoporosis: improves bone mineral density and reduces risk of vertebral and hip fractures. - Paget's disease of bone: normalises abnormal bone turnover. - Glucocorticoid‑induced osteoporosis: helps maintain bone strength in patients receiving long‑term corticosteroid therapy.

Adverse reactions to risedronate are reported across a range of severity.

Common Side Effects: - Upper gastrointestinal discomfort: heartburn, dyspepsia or abdominal pain. - Musculoskeletal pain: transient bone, joint or muscle aches. - Headache: mild to moderate intensity. - Nausea: occasional feeling of queasiness. - Skin reactions: mild rash or erythema.

Serious or Rare Side Effects: - Osteonecrosis of the jaw: exposed bone in the oral cavity, often after dental procedures. - Atypical femoral fracture: low‑energy fracture of the subtrochanteric region. - Severe esophagitis: ulceration or inflammation of the esophagus. - Acute phase reaction: fever, chills or flu‑like symptoms after the first dose.

When prescribing risedronate, clinicians should consider several safety aspects.

- Renal function: assess creatinine clearance before initiating therapy. - Gastro‑intestinal risk: avoid in patients with active peptic ulcer disease or severe esophagitis. - Calcium/Vitamin D status: ensure adequate supplementation to support bone health. - Concomitant medications: review for drugs that may irritate the esophagus. - Pregnancy and lactation: contraindicated unless clearly needed; discuss risks with the prescriber. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Risedronate may interact with several medicines, altering its absorption or increasing toxicity.

Major Interactions (Avoid): - Calcium supplements: concurrent intake reduces risedronate absorption; separate by at least 2 hours. - Antacids containing aluminium or magnesium: may bind the drug and lower bioavailability. - Oral corticosteroids: increase risk of gastrointestinal irritation.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may heighten upper‑GI adverse events. - Proton pump inhibitors (PPIs): potential additive effect on esophageal irritation. - Diuretics (loop or thiazide): monitor electrolytes, especially calcium levels.